Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-08

AUTHORS

A Z Badros, R Vij, T Martin, J A Zonder, L Kunkel, Z Wang, S Lee, A F Wong, R Niesvizky

ABSTRACT

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15 mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy. More... »

PAGES

1707

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/leu.2013.29

DOI

http://dx.doi.org/10.1038/leu.2013.29

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023785372

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23364621


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Function Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Insufficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Badros", 
        "givenName": "A Z", 
        "id": "sg:person.01352622437.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352622437.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University School of Medicine, St Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vij", 
        "givenName": "R", 
        "id": "sg:person.01163517522.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163517522.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "The University of California, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin", 
        "givenName": "T", 
        "id": "sg:person.01064755051.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064755051.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zonder", 
        "givenName": "J A", 
        "id": "sg:person.0667071771.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667071771.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Independent Consultant, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kunkel", 
        "givenName": "L", 
        "id": "sg:person.01106404207.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106404207.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Z", 
        "id": "sg:person.01153747066.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153747066.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "S", 
        "id": "sg:person.01050304516.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050304516.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wong", 
        "givenName": "A F", 
        "id": "sg:person.015702763512.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015702763512.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cornell University", 
          "id": "https://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Weill Cornell Medical College, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niesvizky", 
        "givenName": "R", 
        "id": "sg:person.0736002261.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736002261.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.4065/78.1.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003030843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2009.07803.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003568562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2009.07803.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003568562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1034/j.1600-0609.2000.90221.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004546078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2012.182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006680313", 
          "https://doi.org/10.1038/leu.2012.182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.111.039164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007009347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.30.8791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010368281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010603266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-05-425934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011406947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2008-04-149385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021021356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-1950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027164449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2006-09-046409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027361439"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-04-422683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035718204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2011.049767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036939343"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-03-414359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040165478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.1994.tb00190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046564957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.1994.tb00190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046564957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2012.09232.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047125405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.158.17.1889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048714833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1998.00930.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051933965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/blr.2006.25.447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059238419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077852517", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.8147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083944521"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-08", 
    "datePublishedReg": "2013-08-01", 
    "description": "This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80\u2009ml/min, 50-80\u2009ml/min, 30-49\u2009ml/min, <30\u2009ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15\u2009mg/m(2) (Cycle 1), 20\u2009mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15\u2009mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/leu.2013.29", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "name": "Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety", 
    "pagination": "1707", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "71518d3a1d422130e46299f7ee2a46b3e43159f5a647782398587bec6496cd8f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23364621"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8704895"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/leu.2013.29"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023785372"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/leu.2013.29", 
      "https://app.dimensions.ai/details/publication/pub.1023785372"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000435.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/leu201329"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      21 PREDICATES      65 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/leu.2013.29 schema:about N08c735629cee4392b6343dc168216e33
2 N4f0015bf2ae644b98c211d9cd13a8e82
3 N5aca841e3efb4617aef5c1de64656211
4 N65e858dea04049faa2cb17c01c0aab45
5 N68ced265ab7b4a4283c5190511b8d0da
6 N7ccdd9369334424993ff270e7759338a
7 N81ab8868fedc48cd9de63cb02f24ba7d
8 N83d1fee9713948808596b2ba1e878528
9 N90c8aca2fd77434981a8d602c0a5af13
10 Na65e35f6d49a4b1e9654155c4186258a
11 Nb661053956f849e281b5572f7653b2b0
12 Ncf0a31d96c4a448ea9272f6e9ea6b72a
13 Nd415360a0ab248eb837641957e535ddc
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N9282e33ea27b417ba1f203a11901ed44
17 schema:citation sg:pub.10.1038/leu.2012.182
18 sg:pub.10.1038/sj.leu.2404284
19 https://app.dimensions.ai/details/publication/pub.1077852517
20 https://doi.org/10.1001/archinte.158.17.1889
21 https://doi.org/10.1034/j.1600-0609.2000.90221.x
22 https://doi.org/10.1046/j.1365-2141.1998.00930.x
23 https://doi.org/10.1089/blr.2006.25.447
24 https://doi.org/10.1111/j.1365-2141.2009.07803.x
25 https://doi.org/10.1111/j.1365-2141.2012.09232.x
26 https://doi.org/10.1111/j.1600-0609.1994.tb00190.x
27 https://doi.org/10.1124/dmd.111.039164
28 https://doi.org/10.1158/1078-0432.ccr-09-0822
29 https://doi.org/10.1158/1078-0432.ccr-10-1950
30 https://doi.org/10.1158/1078-0432.ccr-11-3007
31 https://doi.org/10.1182/blood-2006-09-046409
32 https://doi.org/10.1182/blood-2008-04-149385
33 https://doi.org/10.1182/blood-2012-03-414359
34 https://doi.org/10.1182/blood-2012-04-422683
35 https://doi.org/10.1182/blood-2012-05-425934
36 https://doi.org/10.1200/jco.2010.28.15_suppl.8147
37 https://doi.org/10.1200/jco.2010.30.8791
38 https://doi.org/10.3324/haematol.2011.049767
39 https://doi.org/10.4065/78.1.21
40 schema:datePublished 2013-08
41 schema:datePublishedReg 2013-08-01
42 schema:description This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15 mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf N3f95135e86a6418b95677ed5cad8efe1
47 N736e7f9460934c418ab8cf6927ba44f8
48 sg:journal.1097065
49 schema:name Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
50 schema:pagination 1707
51 schema:productId N26bd88c84aa9464680126997c0791ab8
52 N3d6d6ca5f32d40c68ea945725bfbba81
53 N3d70fd2c231e417a954bbf1127ceddd9
54 N684ecfd8da19427884c111e4e47a243d
55 N8bfa9fd612884bb1a61f8a0098cba86c
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023785372
57 https://doi.org/10.1038/leu.2013.29
58 schema:sdDatePublished 2019-04-10T17:20
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N7e98b1de24874c92a55aaeb6b55fe5ed
61 schema:url https://www.nature.com/articles/leu201329
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N08c735629cee4392b6343dc168216e33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Multiple Myeloma
67 rdf:type schema:DefinedTerm
68 N0d28a62f6050475b954491ea195d7915 schema:name Independent Consultant, San Francisco, CA, USA
69 rdf:type schema:Organization
70 N0e26c0b2aebb4807b7b33c895f257c4c rdf:first sg:person.015702763512.16
71 rdf:rest Nbea7f4ea5d294326a65a7691f1576156
72 N26bd88c84aa9464680126997c0791ab8 schema:name nlm_unique_id
73 schema:value 8704895
74 rdf:type schema:PropertyValue
75 N3d6d6ca5f32d40c68ea945725bfbba81 schema:name dimensions_id
76 schema:value pub.1023785372
77 rdf:type schema:PropertyValue
78 N3d70fd2c231e417a954bbf1127ceddd9 schema:name doi
79 schema:value 10.1038/leu.2013.29
80 rdf:type schema:PropertyValue
81 N3f95135e86a6418b95677ed5cad8efe1 schema:issueNumber 8
82 rdf:type schema:PublicationIssue
83 N4f0015bf2ae644b98c211d9cd13a8e82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Antineoplastic Agents
85 rdf:type schema:DefinedTerm
86 N5aca841e3efb4617aef5c1de64656211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Kidney Function Tests
88 rdf:type schema:DefinedTerm
89 N65e858dea04049faa2cb17c01c0aab45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Humans
91 rdf:type schema:DefinedTerm
92 N684ecfd8da19427884c111e4e47a243d schema:name readcube_id
93 schema:value 71518d3a1d422130e46299f7ee2a46b3e43159f5a647782398587bec6496cd8f
94 rdf:type schema:PropertyValue
95 N68ced265ab7b4a4283c5190511b8d0da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Female
97 rdf:type schema:DefinedTerm
98 N736e7f9460934c418ab8cf6927ba44f8 schema:volumeNumber 27
99 rdf:type schema:PublicationVolume
100 N76e7c584f64b42dba43452d7f3e3bbf7 rdf:first sg:person.01064755051.50
101 rdf:rest N89903073d76349c4b4c8337e8e17fe69
102 N7ccdd9369334424993ff270e7759338a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 N7e98b1de24874c92a55aaeb6b55fe5ed schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N81ab8868fedc48cd9de63cb02f24ba7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Renal Insufficiency
109 rdf:type schema:DefinedTerm
110 N83d1fee9713948808596b2ba1e878528 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Aged
112 rdf:type schema:DefinedTerm
113 N89903073d76349c4b4c8337e8e17fe69 rdf:first sg:person.0667071771.30
114 rdf:rest N99abc956d6c149078a1e3977c78a4721
115 N8bfa9fd612884bb1a61f8a0098cba86c schema:name pubmed_id
116 schema:value 23364621
117 rdf:type schema:PropertyValue
118 N906baf2b7fa7436b8463bb1122caecb7 schema:name M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
119 rdf:type schema:Organization
120 N90c8aca2fd77434981a8d602c0a5af13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Middle Aged
122 rdf:type schema:DefinedTerm
123 N9282e33ea27b417ba1f203a11901ed44 rdf:first sg:person.01352622437.39
124 rdf:rest Nfb8df8fc5bae485389363f56b7d8a2d2
125 N99abc956d6c149078a1e3977c78a4721 rdf:first sg:person.01106404207.30
126 rdf:rest Ncb240a567cec4ae889bd01c701ac8955
127 Na65e35f6d49a4b1e9654155c4186258a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged, 80 and over
129 rdf:type schema:DefinedTerm
130 Nb661053956f849e281b5572f7653b2b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Treatment Outcome
132 rdf:type schema:DefinedTerm
133 Nbea7f4ea5d294326a65a7691f1576156 rdf:first sg:person.0736002261.25
134 rdf:rest rdf:nil
135 Ncb240a567cec4ae889bd01c701ac8955 rdf:first sg:person.01153747066.24
136 rdf:rest Nee1ac55eedff4799a292d9817c03f96c
137 Ncf0a31d96c4a448ea9272f6e9ea6b72a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Proteasome Inhibitors
139 rdf:type schema:DefinedTerm
140 Nd415360a0ab248eb837641957e535ddc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Oligopeptides
142 rdf:type schema:DefinedTerm
143 Nee1ac55eedff4799a292d9817c03f96c rdf:first sg:person.01050304516.53
144 rdf:rest N0e26c0b2aebb4807b7b33c895f257c4c
145 Nfb8df8fc5bae485389363f56b7d8a2d2 rdf:first sg:person.01163517522.72
146 rdf:rest N76e7c584f64b42dba43452d7f3e3bbf7
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
151 schema:name Clinical Sciences
152 rdf:type schema:DefinedTerm
153 sg:journal.1097065 schema:issn 0887-6924
154 1476-5551
155 schema:name Leukemia
156 rdf:type schema:Periodical
157 sg:person.01050304516.53 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
158 schema:familyName Lee
159 schema:givenName S
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050304516.53
161 rdf:type schema:Person
162 sg:person.01064755051.50 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
163 schema:familyName Martin
164 schema:givenName T
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064755051.50
166 rdf:type schema:Person
167 sg:person.01106404207.30 schema:affiliation N0d28a62f6050475b954491ea195d7915
168 schema:familyName Kunkel
169 schema:givenName L
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106404207.30
171 rdf:type schema:Person
172 sg:person.01153747066.24 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
173 schema:familyName Wang
174 schema:givenName Z
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153747066.24
176 rdf:type schema:Person
177 sg:person.01163517522.72 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
178 schema:familyName Vij
179 schema:givenName R
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163517522.72
181 rdf:type schema:Person
182 sg:person.01352622437.39 schema:affiliation N906baf2b7fa7436b8463bb1122caecb7
183 schema:familyName Badros
184 schema:givenName A Z
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352622437.39
186 rdf:type schema:Person
187 sg:person.015702763512.16 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
188 schema:familyName Wong
189 schema:givenName A F
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015702763512.16
191 rdf:type schema:Person
192 sg:person.0667071771.30 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
193 schema:familyName Zonder
194 schema:givenName J A
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667071771.30
196 rdf:type schema:Person
197 sg:person.0736002261.25 schema:affiliation https://www.grid.ac/institutes/grid.5386.8
198 schema:familyName Niesvizky
199 schema:givenName R
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736002261.25
201 rdf:type schema:Person
202 sg:pub.10.1038/leu.2012.182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006680313
203 https://doi.org/10.1038/leu.2012.182
204 rdf:type schema:CreativeWork
205 sg:pub.10.1038/sj.leu.2404284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033553106
206 https://doi.org/10.1038/sj.leu.2404284
207 rdf:type schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1077852517 schema:CreativeWork
209 https://doi.org/10.1001/archinte.158.17.1889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048714833
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1034/j.1600-0609.2000.90221.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004546078
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1046/j.1365-2141.1998.00930.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051933965
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1089/blr.2006.25.447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059238419
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1111/j.1365-2141.2009.07803.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003568562
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1111/j.1365-2141.2012.09232.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047125405
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1111/j.1600-0609.1994.tb00190.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046564957
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1124/dmd.111.039164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007009347
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1158/1078-0432.ccr-09-0822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010603266
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1158/1078-0432.ccr-10-1950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027164449
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1158/1078-0432.ccr-11-3007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026589995
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1182/blood-2006-09-046409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027361439
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1182/blood-2008-04-149385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021021356
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1182/blood-2012-03-414359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040165478
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1182/blood-2012-04-422683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035718204
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1182/blood-2012-05-425934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011406947
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2010.28.15_suppl.8147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083944521
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2010.30.8791 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010368281
244 rdf:type schema:CreativeWork
245 https://doi.org/10.3324/haematol.2011.049767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036939343
246 rdf:type schema:CreativeWork
247 https://doi.org/10.4065/78.1.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003030843
248 rdf:type schema:CreativeWork
249 https://www.grid.ac/institutes/grid.254444.7 schema:alternateName Wayne State University
250 schema:name Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
253 schema:name The University of California, San Francisco, CA, USA
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
256 schema:name Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.4367.6 schema:alternateName Washington University in St. Louis
259 schema:name Washington University School of Medicine, St Louis, MO, USA
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.5386.8 schema:alternateName Cornell University
262 schema:name Weill Cornell Medical College, New York, NY, USA
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...